The New Ministry of Health Regulation for the Market, Patients, and European Integration. What Does It Mean?

Today, an extremely important discussion is underway in Ukraine on the harmonization of future new rules in the field of medicine with EU Regulation No. 536/2014. This document mainly concerns clinical trials, but the changes will affect not only them. The Ukrainian system of conducting clinical trials has found itself at a strategic choice point. On the one hand, there is a course for harmonization with European legislation and strengthening the scientific component of medicine. On the other hand, there is concern in the business community about the risks of reducing the market, investments and patients' access to innovative treatment. The new procedure for conducting clinical trials, prepared by the Ministry of Health, has already caused widespread discussion among industry experts and has not passed us by.

In response to an appeal from the professional community, the Ministry of Health reported:

-Ukraine is moving towards full harmonization with EU Regulation No. 536/2014 on clinical trials.

-The new order should introduce clear, transparent, and non-discriminatory research procedures.

-The document has already undergone public discussion in 2025 and has been submitted for state registration.

-The launch of the new system will be synchronized with the start of work of the state control body on January 1, 2027.

The Ministry of Health emphasizes that the goal of the changes is to protect patients' rights, develop the industry, and attract international investment. At the same time, the ministry reported that it does not plan to introduce regulations that limit research to university clinics only, and the received proposals are still being finalized to find a balance between science and the market.

Representatives of the clinical research industry support the development of university clinics, strengthening academic science, and integration into the European research space. However, they warn against decisions that could limit the range of institutions where research is allowed, reduce Ukraine's investment attractiveness, and reduce patients' access to innovative therapies.

According to estimates by the association's specialized subcommittee, the number of studies could be reduced by up to 75%, with a potential loss of $100–150 million in annual market volume, and a loss of $13–20 million in tax revenues each year. In wartime, such losses could have not only economic but also socio-medical dimensions.

Clinical research today is not just about medicine. It is global competition for investments, patient access to the latest therapies, development of research centers, integration into the European healthcare space.

EU Regulation No. 536/2014 indeed requires transparency of procedures, uniform ethical and safety standards, and open access to the participation of research centers. That is why the key question of the discussion is: how to strengthen academic medicine without destroying the clinical research market?

The least heard in the public debate are the voices of those for whom clinical trials exist - patients. For thousands of people in Ukraine, participation in a trial means access to innovative treatment that is not yet on the market; free therapy and diagnostics; a chance where standard medicine has already exhausted its possibilities. Any reduction in trials automatically means fewer chances of life and recovery.

The situation surrounding the new order demonstrates: Ukraine is entering a phase of profound transformation of medical science. Ahead is a difficult balance between: state regulation, scientific interests, industry economics, patient rights, and European integration. Not only the fate of the clinical research market, but also Ukraine's place in the European medical ecosystem of the next decade depends on how well-considered the final decision will be.